About Us

Overview

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company
committed to developing innovative scFv antibody-based therapies
for the treatment of patients with cancers.
Our proprietary platform technology, Eumbody System™,
enables to develop and detect a scFv-based product candidates
that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.

We are committed to help patients with severe diseases
by bringing life-changing therapies to the patients in need.

Optieum Biotechnologies Inc.

HQ: 454 Shitsukawa, Toon-shi, Ehime, Japan
Representative: Shun Nishioka
Foundation: 30 June , 2020

Technology

Eumbody System™

Optieum Biotechnologies’s Eumbody System™ is a proprietary platform technology
for the development of next-generation scFv antibody.
Our technology enables to generate the new scFv expressing CAR-T cells with greater proliferation capacity and longevity, enabling superior reactivity against advanced tumors and minimized adverse effects.

 We are open for a partnership to jointly develop a next generation immuno-oncology products.

Partnering


Optieum Biotechnologies
has built a comprehensive intellectual
property portfolio to encompass
scFv screening technologies.
To discuss a potential partnership
with Optieum Biotechnologies,
please contact Shun Nishioka
from the contact form below.

News Release

2021-09-30
Optieum Biotechnologies
Optieum Biotechnologies Raises JPY 290 million ($ 2.6 million) in Seed Round Funding
　We are pleased to announce that Optieum Biotechnologies Inc. has raised JPY 290 million[...]
2021-03-19
Optieum Biotechnologies
Announcement of Research Collaboration with Daiichi-Sankyo
　We are pleased to announce that Optieum Biotechnologies Inc. has entered into a researc[...]
2021-03-02
Optieum Biotechnologies
Publication Announcement on Eumbody Sysem™
　We are pleased to announce that co-founder of Optieum Biotechnologies, Dr. Toshiki Ochi[...]

Contact Us